Fig. 4: Overall survival according to primary tumour location in molecular subgroups.

According to mutation status; BRAF-V600Emt (a), RASmt (b), and RAS&BRAFwt (c), and according to mutation status in patients with proficient mismatch repair; BRAF-V600Emt (d), RASmt (e), and RAS&BRAFwt (f).